An interventional study of Dedicated breast CT(BCT) in Breast Cancer, sponsored by University of Arizona. Recruiting at 1 site in United States. Open to female participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-24.
Sponsored by University of Arizona · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Breast Neoplasms by University of Arizona — 3 open to participants now, 4 under way, none of them phase 3. Breast Neoplasms · University of Arizona.
Among the 32 studies in Breast Neoplasms by University of Arizona, this one has the largest planned enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2025, is one of 10 with no phase, and was the 24th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →3 of the 32 studies in Breast Neoplasms by University of Arizona are open now, in 1 country. Recruiting first, the newest first:
University of Arizona · Sites in United States
Ages 18+ · Healthy volunteers
University of Arizona
Ages 40+ · Women only · Healthy volunteers
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 40 Years and older · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 600 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 28 across the 28 interventional studies, 83 across the 4 observational. Of the 25 that completed or were terminated, 10 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Arizona is the lead sponsor of 477 studies on the registry; 88 are open to participants now.
Of its 51 completed or terminated interventional studies of FDA-regulated products, 30 (59%) have results posted.
3 of the studies in Breast Neoplasms by University of Arizona that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07705100University of ArizonaClinical Feasibility Study of Upright, Low-dose, High-resolution, 3D Breast CT (UBCT). | 2026-12-31 |
| NCT05715255University of ArizonaAdaptive Symptom Self-Management Immunotherapy Study | 2027-04-30 |
| NCT05676255University of ArizonaThe Breast Cancer Survivors and Partners Online Research Together (SUPORT) Project | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 32 studies in Breast Neoplasms by University of Arizona, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is being performed to find out if a new kind of breast imaging (called dedicated breast CT or BCT) can help doctors to see the small structures in breast tissue more clearly. The investigators also want to find out if using the BCT will provide a more accurate diagnosis of breast cancer.
The breast imaging device that will be used in this study (breast computed tomography or BCT) is not FDA-approved for this use so this is a research study. The machine has been redesigned to see if doctors can see smaller structures and use a lower radiation dose.
The breast CT device will take multiple pictures of the subject's breast and create a 3-D image of the breast. It does not compress or squash the breast like a mammogram.
Inclusion criteria: All subjects that are eligible to participate in the study will be women who satisfy all of the inclusion criteria stated below:
Exclusion criteria: Subjects that present with any of the criteria listed below will be excluded:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All subjects will undergo bilateral breast CT (BCT) imaging exam.
Diagnostic Test: Dedicated breast CT(BCT)
The breast CT device will take multiple pictures of the subject's uncompressed breast and creates a 3-D image of the breast.
Also known as: BCT
Diagnostic accuracy
The diagnostic accuracy of BCT will be determined from a multi-reader, multi-case reader study.
Time frame: 12 months after completion of accrual
Started Aug 2025 (actual). Primary completion is estimated for Dec 2028, 40 months after the start.
Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 40 months is above that.
Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.